Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1851 results
January 2020
-
Press release
Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
Mayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1 Mayzent… -
Featured News
Novartis at J.P Morgan 2020
From January 13-16 2020, Novartis attended the J.P Morgan Healthcare Conference in San Francisco. -
Story Discovery
Sourcing innovation, strategically
Phil Gotwals talks about his vision for the future of business development for research.
-
Press release
Novartis ligelizumab (QGE031) more effective than Xolair® at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticaria
Data show ligelizumab binds to immunoglobulin E (IgE), a key driver of chronic spontaneous urticaria (CSU), with significantly higher affinity than current standard of care Xolair (omalizumab)1 … -
Press release
Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran
Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL… -
Ad hoc release
Novartis completes tender offer for all outstanding shares of The Medicines Company
Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger…
December 2019
-
Press release
AveXis Community Statement on Global Managed Access Program for AVXS-101
Dear SMA Community, Since its U.S. approval, AveXis has had increasing demand from families outside of the U.S. for access to AVXS-101. While we are pursuing registration in close to three dozen… -
Story People and Culture
Parental Leave at Novartis: Michael's story
At Novartis, we celebrate life and recognize moments that matter. Michael Wieser shares his experience of parental leave and becoming a father of two.
-
Ad hoc release
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipiprant was well tolerated with adverse events balanced across… -
Press release
Novartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD
In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one1 In a pre-specified secondary endpoint, fewer patients had intra-… -
Press release
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results for Kisqali plus fulvestrant, reducing the risk of death by almost 30… -
Press release
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients1-3 Fewer known CAR-T cell therapy…